Phase 1b DV281 With an Anti-PD-1 Inhibitor in NSCLC
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Moores Uc San Diego Cancer Center
La Jolla, California, United States
- Ronald Reagan University of California Los Angeles Medical Center
Santa Monica, California, United States
- Allina Health, Virginia Piper Cancer Institute
Minneapolis, Minnesota, United States
- Sarah Cannon Research Institute
Nashville, Tennessee, United States
- Virginia Cancer Specialists
Fairfax, Virginia, United States
- Seattle Cancer Care Alliance
Seattle, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 20 Sept 2017
- Primary completion
- 19 Sept 2019
- Completion
- 19 Sept 2019
- Last update posted
- 17 Jun 2020
- Registered enrollment
- 26
- Registry id
- NCT03326752
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.